JonesResearch analyst Soumit Roy downgraded Essa Pharma (EPIX) to Hold from Buy with no price target after the board decided to terminate all trials to conserve cash. The firm, which says “we were wrong in our assessment of masofaniten’s potential,” expects the stock to trade at a 40%-50% discount to cash per share of $2.64 and awaits comments from management on the future steps they plan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPIX: